日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

ALT-803(一种 IL-15 超激动剂)与 nivolumab 联合用于治疗转移性非小细胞肺癌患者:一项非随机、开放标签、1b 期试验

John M Wrangle, Vamsidhar Velcheti, Manish R Patel, Elizabeth Garrett-Mayer, Elizabeth G Hill, James G Ravenel, Jeffrey S Miller, Mohammad Farhad, Kate Anderton, Kathryn Lindsey, Michele Taffaro-Neskey, Carol Sherman, Samantha Suriano, Marzena Swiderska-Syn, Amy Sion, Joni Harris, Andie R Edwards, J

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma

PD-1/PD-L1 相互作用和 HLA-DR/IDO-1 的定量空间分析可预测转移性黑色素瘤抗 PD-1 疗法的效果改善

Douglas B Johnson #, Jennifer Bordeaux #, Ju Young Kim, Christine Vaupel, David L Rimm, Thai H Ho, Richard W Joseph, Adil I Daud, Robert M Conry, Elizabeth M Gaughan, Leonel F Hernandez-Aya, Anastasios Dimou, Pauline Funchain, James Smithy, John S Witte, Svetlana B McKee, Jennifer Ko, John M Wrangle

β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity

β-catenin 和 PI3Kδ 抑制可扩增前体 Th17 细胞,增强干细胞特性和抗肿瘤活性

Kinga Majchrzak, Michelle H Nelson, Jacob S Bowers, Stefanie R Bailey, Megan M Wyatt, John M Wrangle, Mark P Rubinstein, Juan C Varela, Zihai Li, Richard A Himes, Sherine Sl Chan, Chrystal M Paulos